- Research works
- 1 ▼ 38% vs 2013–17
- Citations
- 12 9.8 per fractional work
- Top-10% rate
- 69.4% record average 16.5%
- Open access
- 64% world 28%
Not ranked overall: HelixBind (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does HelixBind (United States) publish most on?
By volume in 2022–2025: Bacterial Identification and Susceptibility Testing, Sepsis Diagnosis and Treatment, Neonatal and Maternal Infections and Infective Endocarditis Diagnosis and Management.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Bacterial Identification and Susceptibility Testing Clinical Biochemistry 0 works
- 2 Sepsis Diagnosis and Treatment Epidemiology 0 works
- 3 Neonatal and Maternal Infections Public Health, Environmental and Occupational Health 0 works
- 4 Infective Endocarditis Diagnosis and Management Epidemiology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has HelixBind (United States)'s research output changed?
Output in 2018–2022 was 38% lower than in 2013–2017.
Other research institutions in Marlborough
- Boston Scientific (United States)
- Sumitomo Dainippon Pharma (United States)
- Sunovion (United States)
- Hologic (United States)
- Hottinger Baldwin Messtechnik (United States)
- Advanced Cell Technology (United States)
- Phio Pharmaceuticals (United States)
- CardioFocus (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.